vs
Side-by-side financial comparison of AMN HEALTHCARE SERVICES INC (AMN) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.3B vs $1.4B, roughly 1.6× AMN HEALTHCARE SERVICES INC). Zoetis runs the higher net margin — 26.6% vs 4.5%, a 22.1% gap on every dollar of revenue. On growth, AMN HEALTHCARE SERVICES INC posted the faster year-over-year revenue change (100.0% vs 2.9%). Over the past eight quarters, AMN HEALTHCARE SERVICES INC's revenue compounded faster (36.4% CAGR vs -2.1%).
AMN Healthcare Services Inc. is a leading US healthcare sector workforce solutions and staffing provider. It offers temporary and permanent placement for nurses, physicians, allied health and other clinical/non-clinical staff, plus workforce management tools and consulting for hospitals, clinics and other medical facilities.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
AMN vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $2.3B |
| Net Profit | $62.2M | $601.0M |
| Gross Margin | 26.8% | 71.7% |
| Operating Margin | 8.5% | — |
| Net Margin | 4.5% | 26.6% |
| Revenue YoY | 100.0% | 2.9% |
| Net Profit YoY | — | -0.2% |
| EPS (diluted) | $1.59 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.4B | $2.3B | ||
| Q4 25 | $748.2M | $2.4B | ||
| Q3 25 | $634.5M | $2.4B | ||
| Q2 25 | $658.2M | $2.5B | ||
| Q1 25 | $689.5M | $2.2B | ||
| Q4 24 | $734.7M | $2.3B | ||
| Q3 24 | $687.5M | $2.4B | ||
| Q2 24 | $740.7M | $2.4B |
| Q1 26 | $62.2M | $601.0M | ||
| Q4 25 | $-7.7M | $603.0M | ||
| Q3 25 | $29.3M | $721.0M | ||
| Q2 25 | $-116.2M | $718.0M | ||
| Q1 25 | $-1.1M | $631.0M | ||
| Q4 24 | $-187.5M | $581.0M | ||
| Q3 24 | $7.0M | $682.0M | ||
| Q2 24 | $16.2M | $624.0M |
| Q1 26 | 26.8% | 71.7% | ||
| Q4 25 | 26.1% | 70.2% | ||
| Q3 25 | 29.1% | 71.5% | ||
| Q2 25 | 29.8% | 73.6% | ||
| Q1 25 | 28.7% | 72.0% | ||
| Q4 24 | 29.8% | 69.5% | ||
| Q3 24 | 31.0% | 70.6% | ||
| Q2 24 | 31.0% | 71.7% |
| Q1 26 | 8.5% | — | ||
| Q4 25 | 1.1% | 31.9% | ||
| Q3 25 | 7.5% | 37.0% | ||
| Q2 25 | -18.8% | 36.7% | ||
| Q1 25 | 1.8% | 36.5% | ||
| Q4 24 | -27.6% | 31.6% | ||
| Q3 24 | 3.2% | 36.6% | ||
| Q2 24 | 5.1% | 33.0% |
| Q1 26 | 4.5% | 26.6% | ||
| Q4 25 | -1.0% | 25.3% | ||
| Q3 25 | 4.6% | 30.0% | ||
| Q2 25 | -17.7% | 29.2% | ||
| Q1 25 | -0.2% | 28.4% | ||
| Q4 24 | -25.5% | 25.1% | ||
| Q3 24 | 1.0% | 28.6% | ||
| Q2 24 | 2.2% | 26.4% |
| Q1 26 | $1.59 | $1.42 | ||
| Q4 25 | $-0.19 | $1.37 | ||
| Q3 25 | $0.76 | $1.63 | ||
| Q2 25 | $-3.02 | $1.61 | ||
| Q1 25 | $-0.03 | $1.41 | ||
| Q4 24 | $-4.90 | $1.29 | ||
| Q3 24 | $0.18 | $1.50 | ||
| Q2 24 | $0.42 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $560.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | — |
| Total Assets | $2.6B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $560.7M | — | ||
| Q4 25 | $34.0M | — | ||
| Q3 25 | $52.6M | $2.1B | ||
| Q2 25 | $41.5M | $1.4B | ||
| Q1 25 | $55.8M | $1.7B | ||
| Q4 24 | $10.6M | $2.0B | ||
| Q3 24 | $30.6M | $1.7B | ||
| Q2 24 | $48.0M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | $767.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $642.1M | $3.3B | ||
| Q3 25 | $644.4M | $5.4B | ||
| Q2 25 | $607.6M | $5.0B | ||
| Q1 25 | $715.1M | $4.7B | ||
| Q4 24 | $706.6M | $4.8B | ||
| Q3 24 | $890.7M | $5.2B | ||
| Q2 24 | $876.9M | $5.0B |
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.1B | $15.5B | ||
| Q3 25 | $2.1B | $15.2B | ||
| Q2 25 | $2.2B | $14.5B | ||
| Q1 25 | $2.4B | $14.1B | ||
| Q4 24 | $2.4B | $14.2B | ||
| Q3 24 | $2.7B | $14.4B | ||
| Q2 24 | $2.8B | $14.2B |
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $562.5M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 9.04× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $562.5M | — | ||
| Q4 25 | $75.6M | $893.0M | ||
| Q3 25 | $22.7M | $938.0M | ||
| Q2 25 | $78.5M | $486.0M | ||
| Q1 25 | $92.7M | $587.0M | ||
| Q4 24 | $72.8M | $905.0M | ||
| Q3 24 | $66.7M | $951.0M | ||
| Q2 24 | $99.5M | $502.0M |
| Q1 26 | — | — | ||
| Q4 25 | $67.6M | $732.0M | ||
| Q3 25 | $14.8M | $805.0M | ||
| Q2 25 | $68.7M | $308.0M | ||
| Q1 25 | $82.7M | $438.0M | ||
| Q4 24 | $56.6M | $689.0M | ||
| Q3 24 | $47.4M | $784.0M | ||
| Q2 24 | $72.2M | $370.0M |
| Q1 26 | — | — | ||
| Q4 25 | 9.0% | 30.7% | ||
| Q3 25 | 2.3% | 33.5% | ||
| Q2 25 | 10.4% | 12.5% | ||
| Q1 25 | 12.0% | 19.7% | ||
| Q4 24 | 7.7% | 29.7% | ||
| Q3 24 | 6.9% | 32.8% | ||
| Q2 24 | 9.8% | 15.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 6.7% | ||
| Q3 25 | 1.2% | 5.5% | ||
| Q2 25 | 1.5% | 7.2% | ||
| Q1 25 | 1.4% | 6.7% | ||
| Q4 24 | 2.2% | 9.3% | ||
| Q3 24 | 2.8% | 7.0% | ||
| Q2 24 | 3.7% | 5.6% |
| Q1 26 | 9.04× | — | ||
| Q4 25 | — | 1.48× | ||
| Q3 25 | 0.77× | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | 9.54× | 1.39× | ||
| Q2 24 | 6.13× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMN
Segment breakdown not available.
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
